Allied Market Research

2024

Japan Orphan Drugs Market

Japan Orphan Drugs Market Size, Share, Competitive Landscape and Trend Analysis Report by DISEASE TYPE (ONCOLOGIC DISEASES, METABOLIC DISEASES, HEMATOLOGIC AND IMMUNOLOGIC DISEASES, INFECTIOUS DISEASES, NEUROLOGIC DISEASES, OTHER RARE DISEASES) and by INDICATION (NON-HODGKIN LYMPHOMA, ACUTE MYELOID LEUKEMIA, CYSTIC FIBROSIS, GLIOMA, PANCREATIC CANCER, OVARIAN CANCER, MULTIPLE MYELOMA, DUCHENNE MUSCULAR DYSTROPHY, GRAFT VS HOST DISEASE, RENAL CELL CARCINOMA, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Japan Orphan Drugs Market Report Highlights

Aspects Details
Japan Orphan Drugs Market By DISEASE TYPE
By DISEASE TYPE
  • ONCOLOGIC DISEASES
  • METABOLIC DISEASES
  • HEMATOLOGIC AND IMMUNOLOGIC DISEASES
  • INFECTIOUS DISEASES
  • NEUROLOGIC DISEASES
  • OTHER RARE DISEASES
Japan Orphan Drugs Market By INDICATION
By INDICATION
  • NON-HODGKIN LYMPHOMA
  • ACUTE MYELOID LEUKEMIA
  • CYSTIC FIBROSIS
  • GLIOMA
  • PANCREATIC CANCER
  • OVARIAN CANCER
  • MULTIPLE MYELOMA
  • DUCHENNE MUSCULAR DYSTROPHY
  • GRAFT VS HOST DISEASE
  • RENAL CELL CARCINOMA
  • Others
Key Market Players
Key Market Players

Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Pfizer, Inc., Kyowa Hakko Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Merck KGaA, Shionogi & Co., Ltd., Daiichi Sankyo Company, Limited, Eisai Co., Ltd.

Loading Table Of Content...

Japan Orphan Drugs Market

Global Opportunity Analysis and Industry Forecast, 2023-2032